Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2022-03-07 Earnings Release
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis
Earnings Release Classification · 95% confidence The document is a press release titled 'Inventiva reports its 2021 Full-Year Results'. It provides a summary of financial highlights, including cash position, R&D expenses, and net income, along with a detailed income statement table. While it contains financial data, it is structured as a press release (indicated by the 'PRESS RELEASE' header and the narrative style) rather than a full 10-K or formal annual report. According to the filing definitions, an initial announcement of periodic financial results is classified as an Earnings Release (ER). FY 2021
2022-03-07 English
Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis
Earnings Release Classification · 100% confidence The document is titled "Inventiva reports its 2021 Full-Year Results" and contains detailed financial tables, including an income statement comparing 2021 to 2020, R&D expenses, cash position, and management commentary on the full fiscal year. This structure and content strongly indicate a comprehensive annual financial report. Although it is presented as a press release, the depth of the financial data (including a full IFRS income statement table) suggests it is the official release accompanying the Annual Report (10-K) or serving as the primary disclosure of annual results. Since it explicitly covers the 'Full-Year Results' and provides detailed financial performance metrics for the entire year, it aligns best with the scope of an Annual Report disclosure, even if it is not the formal 10-K filing itself. Given the options, '10-K' is the closest fit for a comprehensive full-year results disclosure, although 'ER' (Earnings Release) is also plausible for a results announcement. However, the level of detail (full income statement, balance sheet components mentioned, full year focus) pushes it beyond a typical quarterly earnings release (ER) towards the annual reporting standard. I will classify it as 10-K based on the 'Full-Year Results' focus and comprehensive financial detail. FY 2021
2022-03-07 English
Inventiva annonce sa participation à plusieurs conférences investisseurs en mars 2022
Report Publication Announcement Classification · 99% confidence The document is an announcement from Inventiva stating that its management team will participate in several investor conferences in March 2022. It details the names, dates, times, and formats of these events (Cowen 42nd Annual Health Care Conference and Invest securities Biomed Event). This type of communication, which informs investors about upcoming opportunities to hear presentations or meet management, aligns best with an Investor Presentation or general corporate update related to investor relations activities. Since it is specifically about management presenting at investor conferences, it strongly relates to Investor Presentation (IP) materials or general corporate updates. Given the options, 'Investor Presentation' (IP) is the closest fit as these conferences often involve the company presenting its investment case, even if the document itself is just the announcement of attendance. It is not a formal regulatory filing like 10-K, ER, or IR, nor is it a transcript (CT) or a specific report (AR, SR). It is an announcement about future investor engagement.
2022-03-01 French
Inventiva announces participation at several conferences in March 2022
Report Publication Announcement Classification · 99% confidence The document is an announcement from Inventiva stating that its leadership will participate in two upcoming investor conferences in March 2022. It details the names, dates, times, and formats of these events (Cowen 42nd Annual Health Care Conference and Invest securities Biomed Event). This type of communication, which informs investors about planned presentations or meetings at industry events, is best classified as an Investor Presentation (IP) or a general announcement related to investor relations activities. Since the document itself is an announcement about future participation rather than the presentation slides or a transcript of a call, and it specifically mentions investor meetings and corporate presentations, 'Investor Presentation' (IP) is the most fitting category, as it relates directly to investor engagement activities. It is not a formal regulatory filing like 10-K or ER, nor is it a proxy statement or dividend notice. It is an announcement of investor engagement.
2022-03-01 English
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2021
Report Publication Announcement Classification · 98% confidence The document is titled "Inventiva annonce la date de publication et de présentation de ses résultats financiers 2021" (Inventiva announces the date of publication and presentation of its 2021 financial results). It explicitly states when the 2021 financial results will be published (March 7, 2022) and when a conference call/webcast presentation will occur (March 8, 2022). This document is not the financial report itself (like an IR or 10-K), but rather an announcement about the timing and logistics of the upcoming release and discussion of those results. According to Rule 2, when a document announces the publication of a report, it should be classified as a Report Publication Announcement (RPA).
2022-02-28 French
Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results
Report Publication Announcement Classification · 98% confidence The document is an announcement titled "Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results." It explicitly states when the full-year financial results will be released (March 7, 2022) and when management will host a conference call/webcast to present them (March 8, 2022). This structure—announcing the timing of a future report release and associated call—fits the definition of a Report Publication Announcement (RPA). It is not the full financial report (10-K or IR) itself, nor is it the transcript of the call (CT).
2022-02-28 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.